ALPH Stock Overview
AlphaHelix Molecular Diagnostics AB (publ) develops, manufactures, and sells products for PCR/QPCR.
AlphaHelix Molecular Diagnostics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr0.74|
|52 Week High||kr3.57|
|52 Week Low||kr0.70|
|1 Month Change||-26.10%|
|3 Month Change||-35.15%|
|1 Year Change||-70.26%|
|3 Year Change||13.23%|
|5 Year Change||-42.95%|
|Change since IPO||-94.11%|
Recent News & Updates
Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
|ALPH||SE Life Sciences||SE Market|
Return vs Industry: ALPH underperformed the Swedish Life Sciences industry which returned -51.8% over the past year.
Return vs Market: ALPH underperformed the Swedish Market which returned -22.1% over the past year.
|ALPH Average Weekly Movement||12.5%|
|Life Sciences Industry Average Movement||7.9%|
|Market Average Movement||7.2%|
|10% most volatile stocks in SE Market||12.7%|
|10% least volatile stocks in SE Market||4.6%|
Stable Share Price: ALPH is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: ALPH's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
AlphaHelix Molecular Diagnostics AB (publ) develops, manufactures, and sells products for PCR/QPCR. It also operates as a supplier and partner for clinical laboratories and research laboratories in the Nordic region. The company provides smarter reagents, consumables, and instruments for customers in research and diagnostics.
AlphaHelix Molecular Diagnostics Fundamentals Summary
|ALPH fundamental statistics|
Is ALPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALPH income statement (TTM)|
|Cost of Revenue||kr41.42m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.078|
|Net Profit Margin||10.28%|
How did ALPH perform over the long term?See historical performance and comparison
Is ALPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALPH?
Other financial metrics that can be useful for relative valuation.
|What is ALPH's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does ALPH's PE Ratio compare to its peers?
|ALPH PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
MAGLE Magle Chemoswed Holding
GENO Genovis AB (publ.)
ALIF B AddLife
ALPH AlphaHelix Molecular Diagnostics
Price-To-Earnings vs Peers: ALPH is good value based on its Price-To-Earnings Ratio (9.4x) compared to the peer average (55x).
Price to Earnings Ratio vs Industry
How does ALPH's PE Ratio compare vs other companies in the European Life Sciences Industry?
Price-To-Earnings vs Industry: ALPH is good value based on its Price-To-Earnings Ratio (9.4x) compared to the Swedish Life Sciences industry average (48.5x)
Price to Earnings Ratio vs Fair Ratio
What is ALPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||9.4x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ALPH's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ALPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ALPH (SEK0.74) is trading below our estimate of fair value (SEK0.8)
Significantly Below Fair Value: ALPH is trading below fair value, but not by a significant amount.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is AlphaHelix Molecular Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AlphaHelix Molecular Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether AlphaHelix Molecular Diagnostics is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
How has AlphaHelix Molecular Diagnostics performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALPH has high quality earnings.
Growing Profit Margin: ALPH's current net profit margins (10.3%) are higher than last year (8.6%).
Past Earnings Growth Analysis
Earnings Trend: ALPH's earnings have grown significantly by 55.1% per year over the past 5 years.
Accelerating Growth: ALPH's earnings growth over the past year (117%) exceeds its 5-year average (55.1% per year).
Earnings vs Industry: ALPH earnings growth over the past year (117%) exceeded the Life Sciences industry 92.3%.
Return on Equity
High ROE: ALPH's Return on Equity (21.1%) is considered high.
Discover strong past performing companies
How is AlphaHelix Molecular Diagnostics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ALPH's short term assets (SEK22.2M) exceed its short term liabilities (SEK6.9M).
Long Term Liabilities: ALPH's short term assets (SEK22.2M) exceed its long term liabilities (SEK1.7M).
Debt to Equity History and Analysis
Debt Level: ALPH has more cash than its total debt.
Reducing Debt: ALPH's debt to equity ratio has reduced from 11.6% to 2.2% over the past 5 years.
Debt Coverage: ALPH's debt is well covered by operating cash flow (309.8%).
Interest Coverage: ALPH's interest payments on its debt are well covered by EBIT (121.9x coverage).
Discover healthy companies
What is AlphaHelix Molecular Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALPH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALPH has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mikael Havsjo (66 yo)
Mr. Mikael Havsjö serves as the Chief Executive Officer at AlphaHelix Molecular Diagnostics AB (publ) and Techtum Lab AB. He was the Chairman of AlphaHelix Molecular Diagnostics AB (publ) and has been its...
CEO Compensation Analysis
Compensation vs Market: Mikael's total compensation ($USD9.31K) is below average for companies of similar size in the Swedish market ($USD232.80K).
Compensation vs Earnings: Mikael's compensation has been consistent with company performance over the past year.
Experienced Board: ALPH's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AlphaHelix Molecular Diagnostics AB (publ)'s employee growth, exchange listings and data sources
- Name: AlphaHelix Molecular Diagnostics AB (publ)
- Ticker: ALPH
- Exchange: NGM
- Founded: NaN
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr46.662m
- Shares outstanding: 63.40m
- Website: https://www.alphahelix.com
Number of Employees
- AlphaHelix Molecular Diagnostics AB (publ)
- Västra Finnbodavägen 4B
- Stockholm County
- 131 30
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/12 00:00|
|End of Day Share Price||2022/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.